DPDavid Thomas Plante

David Thomas Plante

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Thomas Plante has a total of 239 co-authors. Here are the top co-authors by number of shared publications:

  • Jesse D. Cook

    Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, USA

    6 shared publications
  • Jesse D. Cook

    University of Wisconsin – Madison

    5 shared publications
  • Michael R. Goldstein

    Department of Psychiatry Beth Israel Deaconess Medical Center & Harvard Medical School Boston Massachusetts USA

    5 shared publications
  • Paul E. Peppard

    Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, USA

    5 shared publications
  • B.A. Riedner

    University of Wisconsin School of Medicine and Public Health, Department of Psychiatry, Madison, WI, USA

    4 shared publications
  • Erika W. Hagen

    Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin–Madison, Madison, USA

    4 shared publications

Latest Publications

  • Open Access

    Sleep inertia, daytime sleepiness, and falls in older adults of the Wisconsin Sleep Cohort

    by Jesse D Cook, Jodi H Barnet, Jessica J Love, Laurel A Ravelo, Annaliise J Hayrynen, Amanda Rasmuson, Erika W Hagen, Paul E Peppard, David T Plante

    Study Objectives: Examine associations between sleep inertia, daytime sleepiness, and falls in older adults of the Wisconsin Sleep Cohort (WSC). Materials and Methods: Cross-sectional data from WSC participants were used. Participants completed the Sleep Inertia Questionnaire (SIQ) and Epworth Sleepiness Scale (ESS). Elevated sleep inertia (ESI) was defined as the upper quartile (SIQ > 37), while ESS > 10 defined excessive daytime sleepiness (EDS). Falls outcomes included self-reported recurrent (<2 vs 2+) and injurious (no vs yes) falls over the previous year. Logistic regressions examined associations with falls outcomes. Fully adjusted analyses included demographics and outcome-specific sleep, psychiatric, medical, physical, and cognitive covariates. Secondary analyses explored associations with SIQ subscales. Results: The recurrent falls sample included 392 older adults (74.5 ± 6.6 years; 44.9% female), while 162 participants with ≥1 fall comprised the injurious falls sample (75.4 ± 6.6 years; 45.1% female). In unadjusted analyses, higher SIQ scores and ESI were significantly associated with recurrent and injurious falls; however, in fully adjusted analyses, the associations remained significant only for recurrent falls (SIQ: OR = 1.04, 95% CI = 1.00–1.07; ESI: OR = 2.00, 95% CI = 1.07–3.73). Higher ESS scores and EDS were significantly associated with recurrent falls in unadjusted analyses, but not in fully adjusted analyses. Neither ESS nor EDS was associated with injurious falls. In SIQ subscale analyses, Physiological symptoms were most strongly associated with recurrent falls, whereas Cognitive symptoms were most strongly associated with injurious falls. Conclusions: Sleep inertia may represent an important, under-recognized risk factor for falls in older adults.

  • An examination of the effect of dual task on gait in Parkinson's disease and REM sleep behavior disorder

    by Catherine L. Gallagher, Maureen Haebig, Ananya Heroor, Rachna Tiwari, David T. Plante, Ozioma C. Okonkwo, Jessica M. Baker, Laura Buyan-Dent, Teresa Mangin, Kathleen M. Shannon, et al.

  • Open Access

    Correction: Association between sleep inertia and cognitive performance among older adults in the Wisconsin Sleep Cohort study

    by Jessica J. Love, Jesse D. Cook, Erika W. Hagen, Amanda Rasmunon, Laurel A. Ravelo, Mari Palta, Paul E. Peppard, David T. Plante

  • Open Access

    Association between sleep inertia and cognitive performance among older adults in the Wisconsin Sleep Cohort study

    by Jessica J. Love, Jesse D. Cook, Erika W. Hagen, Amanda Rasmunon, Laurel A. Ravelo, Mari Palta, Paul E. Peppard, David T. Plante

    Purpose: Since sleep inertia and hypersomnolence, broadly, have not been adequately studied in the context of neurocognitive performance, this investigation examined associations between sleep inertia severity, other measures of hypersomnolence, and outcomes from a standardized, cognitive testing battery in a well-characterized community-based sample of older adults. Methods: Wisconsin Sleep Cohort participants completed the Sleep Inertia Questionnaire (SIQ), Epworth Sleepiness Scale (ESS), Hypersomnia Severity Index (HSI) and six widely used cognitive tests. Linear regression examined relationships between hypersomnolence measures (SIQ, ESS, and HSI) and cognitive outcomes. Secondary analyses assessed relationships between SIQ subscales (physiological, cognitive, emotional, and responses) and cognitive outcomes. Adjusted models included covariates capturing demographic, psychosocial, sleep, and testing characteristics. Results: The sample ( N = 461) was predominantly non-Hispanic white older adults (average age = 73.84 ± 6.66 years), with majority being male (55.8%). In unadjusted analyses, SIQ total score was associated with Grooved Pegboard (GPB), Trail Making Test-Part B (TMT-B), and Symbol Digits Modalities Test, while neither ESS nor HSI was associated with cognitive outcomes. Significant associations between SIQ and GPB and TMT-B remained in fully adjusted analyses. Physiological, cognitive, and emotional SIQ subscales were also associated with cognitive tests, particularly GPB and TMT-B. Conclusions: This study suggests that sleep inertia may be an important, specific symptom that is associated with cognitive performance in older adults. Future research is indicated to clarify the role of sleep inertia in aging, while exploring its potential value as a risk factor for cognitive impairment and target for intervention to support cognitive health. Brief summary: Current Study/Study Rationale: Sleep inertia is a common sleep-related symptom, yet it remains insufficiently studied, particularly regarding neurocognitive performance. The Sleep Inertia Questionnaire (SIQ) is a validated measure of sleep inertia, but has not been studied in older populations at risk for cognitive impairment. Clarifying relationships between SIQ scores and neurocognitive outcomes may identify those at greater risk for cognitive impairment. Study Impact: Sleep inertia is a common sleep-related symptom, yet it remains insufficiently studied, particularly regarding neurocognitive performance. The Sleep Inertia Questionnaire (SIQ) is a validated measure of sleep inertia, but has not been studied in older populations at risk for cognitive impairment. Clarifying relationships between SIQ scores and neurocognitive outcomes may identify those at greater risk for cognitive impairment.

  • Open Access

    Slow Wave Activity During Nocturnal Sleep in Hypersomnolence Disorder

    by Jesse D. Cook, Brady A. Riedner, Meredith E. Rumble, Michael R. Goldstein, Ana Maria Vascan, Kieulinh M. Tran, David T. Plante

    Slow waves during non‐rapid eye movement (NREM) sleep are associated with the restorative aspects of sleep. Previous research has suggested reduced normalized slow wave activity (SWA), particularly in the first cycle of NREM sleep, as a feature of hypersomnolence disorder (HD); however, the scarcity of existing research highlights the need for replication studies. Thus, the aim of this investigation was to evaluate normalized SWA in patients with HD, relative to healthy sleeper controls (HSC). Nocturnal polysomnography from 37 unmedicated HD clinical patients were compared against 29 HSC. Six‐channel electroencephalographic data from polysomnography was processed according to consensus standards. Normalized SWA (0.5–4.5hz) was calculated from artefact‐free NREM epochs for all‐night data, as well as sleep cycle 1, 2, and 3. Normalized SWA was compared across groups, with adjusted analyses accounting for age, sex, body mass index, and depressive symptomatology. Post hoc analyses compared HD who met objective criteria for idiopathic hypersomnia (HD/IH+), those who did not (HD/IH−), and HSC. HD demonstrated significantly reduced all‐night, normalized SWA in unadjusted analyses across all channels, without significant differences observed in fully adjusted analyses. In cycle 1, HD displayed significantly reduced normalized SWA across all channels in both unadjusted and adjusted analyses. HD/IH+ and HD/IH− were statistically comparable in normalized SWA across all analyses. This study provides further evidence of reduced SWA, particularly during cycle 1 of NREM sleep, as a core feature of HD. Future studies that investigate the causal role of slow waves in the pathophysiology of HD are warranted.

  • Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome

    by Paul A. Chung, Victoria L. Fleming, Kathryn J. Reid, David T. Plante, Christy L. Hom, Beau M. Ances, Benjamin L. Handen, Bradley T. Christian, Elizabeth Head, Mark Mapstone, et al.

    Background and ObjectivesThere is a paucity of research on the role of circadian rhythm disruption in Alzheimer disease (AD)-related cognitive impairments in adults with Down syndrome (DS). The aim...


  • Open Access

    Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study

    by Logan D. Schneider, Chad M. Ruoff, David T. Plante, Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Sarah Akerman, Jessica K. Alexander, Marisa Whalen, et al.

    A phase 4, prospective, open-label study of low-sodium oxybate (LXB) in narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia included novel symptom outcomes important to patients (Jazz DUET; NCT05875974; registered 16 May 2023). Primary results from the narcolepsy cohort, including LXB effectiveness (nighttime sleep/daytime symptoms/overall disease severity) and safety are reported here. DUET included screening, 8-day baseline (BL; off-LXB), 2-8-week LXB dose titration/optimization, 2-week stable-dose, 8-day end-of-treatment (EOT; on-LXB), and safety follow-up periods. At BL and EOT, participants underwent nocturnal polysomnography (PSG) and completed Epworth Sleepiness Scale (ESS; primary endpoint), Narcolepsy Severity Scale (NSS [NT1]; NSS-2 [NT2]), and Patient Global Impression of Severity (PGI-S) and Change (PGI-C); eDiaries for sleep quality and cataplexy (NT1 only) were completed daily for 8 days before PSGs. Least-squares mean (LSM) changes were adjusted for BL values. Thirty-four participants completed the study and were analyzed (NT1, n = 16; NT2, n = 18); LSM (SE) change in ESS score (BL to EOT), - 7.7 (0.9), P < 0.0001. At EOT versus BL, transitions to lighter stages of sleep decreased (LSM [SE] - 13.1 [2.9], P < 0.0001), N3 duration increased (45.0 [8.8] min, P < 0.0001), and nocturnal awakenings decreased (- 3.2 [0.9], P = 0.0013). LSM [SE] changes in NSS and NSS-2 scores were - 19.7 (2.7) and - 11.3 (1.6). Most participants reported improved sleep quality and overall narcolepsy disease and fewer cataplexy attacks. Treatment-emergent adverse events were consistent with the known LXB safety profile. DUET study results demonstrated novel nighttime sleep/daytime symptom improvements in participants with narcolepsy treated with open-label LXB. ClinicalTrials.gov identifier, NCT05875974.


  • Open Access

    The prevalence and incidence of narcolepsy in the United States: a real-world observational study using a validated narcolepsy case definition

    by Somraj Ghosh, Veena Hoffman, Brian Calingaert, David T Plante, Lois E Krahn, Alice Cai, Mary S Anthony, Shreya Dave, Satish Rao, Stephen Crawford

    Study Objectives: Narcolepsy is a chronic condition affecting the sleep/wake cycle that is challenging to diagnose. Epidemiological data from large US-focused studies remain limited, with no validated claims-based case selection definitions for narcolepsy. We estimated the prevalence/incidence of diagnosed narcolepsy (type 1 [NT1], type 2 [NT2], overall) in an insured US population using validated, claims-based narcolepsy case definitions. Materials and Methods: This observational study used HealthVerity administrative claims-linked electronic medical records to develop case definitions identifying individuals with NT1, NT2, and overall narcolepsy from diagnosis, medication, and procedure codes. Claims-based case definition performance (NT1, NT2, overall narcolepsy) was assessed using positive predictive values (PPVs). Prevalence (per 100 000 persons, on December 31, 2023) and annual incidence (per 100 000 person-years [PY], 2020 − 2023) were calculated/adjusted using PPVs for each case definition. Results: Unadjusted point prevalence among individuals with ≥12 months of continuous enrollment were 15.5/100 000 (NT1), 51.1/100 000 (NT2), and 67.0/100 000 (overall narcolepsy). Unadjusted incidence rates were stable from 2020 − 2023 for NT1 (range, 2.0 − 2.3/100 000 PY) but declined across years for NT2 (9.1 − 7.6/100 000 PY) and overall narcolepsy (11.3 − 9.6/100 000 PY). PPVs (95% confidence interval) of NT1, NT2, and overall narcolepsy were 0.81 (0.72 − 0.88), 0.84 (0.75 − 0.91), and 0.80 (0.71 − 0.87), contributing to epidemiologic estimates being reduced by ~20% after PPV adjustment. Prevalence and incidence were higher in females than males. Individuals with NT1 were ~ 4 years younger versus NT2. Conclusions: Validated definitions for narcolepsy can reduce potential misclassification. Our findings highlight a relatively low NT1 prevalence in the US. In contrast, NT2 prevalence estimates were > 3 times higher than NT1.


  • Open Access

    Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study

    by David T. Plante, Alyssa Cairns, Logan D. Schneider, Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Sarah Akerman, Jessica K. Alexander, Marisa Whalen, et al.

    Background and Objectives Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) was a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study of individuals with idiopathic hypersomnia or narcolepsy evaluating safety and effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on sleep and daytime symptoms. Results from the idiopathic hypersomnia cohort are reported here. Methods The DUET study included a screening period (with a 2-week washout for current oxybate users), an 8-day baseline (BL) period, a 2- to 8-week LXB titration period, a 2-week stable-dose period, an 8-day end-of-treatment period (EOT) period, and a 2-week safety follow-up. The primary endpoint was the change in Epworth Sleepiness Scale (ESS) score from BL to EOT. Secondary endpoints for the idiopathic hypersomnia cohort included change in Idiopathic Hypersomnia Severity Scale (IHSS) total score; Patient Global Impression of Change (PGI-C) and Severity (PGI-S) for overall idiopathic hypersomnia disease, sleep inertia, and fatigue; and changes in sleep quality and feeling rested upon awakening (from self-reported daily sleep diary). Exploratory outcomes included sleep patterns measured by actigraphy, the British Columbia Cognitive Complaints Inventory, Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10), and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem. Incidence and severity of treatment-emergent adverse events (TEAEs) were assessed. Results Forty-six participants with idiopathic hypersomnia enrolled and took LXB for ≥ 1 night after the BL period; n = 40 completed. Most enrolled participants were female (80.4%), White (84.8%), and non-Hispanic/Latino (76.1%), with mean (SD) age of 38.1 (11.8) years; 19 (41.3%) were taking concomitant alerting agents. Least squares mean (LSM; standard error [SE]) changes in ESS score and IHSS total score from BL to EOT were − 8.4 (0.7), p < 0.0001, and − 15.5 (1.5), p < 0.0001, respectively. On the PGI-C at EOT, most participants (94.6%; 95% CI 81.8, 99.3) reported improvement in overall idiopathic hypersomnia disease. Additionally, participants showed improvements (BL vs EOT) in sleep quality (36.7% vs 6.7% reporting “poor” or “very poor”) and level of feeling rested upon awakening (73.3% vs 26.7% reporting “slightly” or “not at all rested”), and number of awakenings on actigraphy (LSM [SE] change − 3.4 [0.6], p < 0.0001). Participants also exhibited improved daytime functioning in parallel with reduced nocturnal sleep time. From BL to EOT, LS mean (SE) changes for work time missed, impairment while working, overall work impairment, and activity impairment were − 4.6% (1.8%), p = 0.0179; − 30.7% (3.9%), p < 0.0001; − 32.4% (4.3%), p < 0.0001; and − 37.3% (4.3%), p < 0.0001, respectively. Treatment-emergent adverse events (occurring in ≥ 10% of participants) included nausea (19.6%), dizziness (17.4%), headache (17.4%), and vomiting (10.9%). Conclusions Individuals with idiopathic hypersomnia treated with open-label LXB showed improvements in subjective and objective measures of sleep and symptoms. Treatment-emergent adverse events were consistent with the known safety profile of LXB. This study supports the effectiveness of LXB in treating this condition with a 24-h burden of symptoms. Clinical Trial Registration ClinicalTrials.gov NCT05875974. [Graphical abstract available] Graphical Abstract


  • Open Access

    Prevalence of diagnosed idiopathic hypersomnia among adults in the United States 2019–2023: analysis of healthcare claims

    by Sarah C Markt, Jed Black, Richard K Bogan, Elizabeth T Jensen, Patricia Prince, Adina Estrin, Monica Iyer, Marisa Whalen, Jessica K Alexander, Weiyi Ni, et al.

    Study Objectives: National prevalence estimates for idiopathic hypersomnia (IH) are difficult to obtain. This study estimated the diagnosed IH prevalence among US adults. Methods: Symphony Integrated Dataverse claims (01/2015–12/2023) were analyzed. Eligible patients were aged ≥18 years with at least one medical/prescription claim in the year of interest (2019–2023) and prior year. IH was defined by ≥1 medical claim with an IH diagnosis code. Prevalence was estimated among all eligible patients in two ways: annual (IH diagnoses during year of interest) and all-time (IH diagnoses looking back all-time in the database from 2015 through year of interest). Age- and sex-adjusted prevalence estimates were also calculated using the US Census Bureau. Results: Over 179, 182, 193, 205, and 198 million adults were assessed for diagnosed IH prevalence in each respective year 2019–2023. Unweighted annual prevalence of diagnosed IH from 2019 to 2023 was 12.1, 11.1, 11.0, 10.5, and 11.1 per 100 000 persons, respectively. Unweighted all-time lookback prevalence of diagnosed IH from 2019 to 2023 was 32.7, 37.3, 40.6, 43.3, and 49.0 per 100 000 persons, respectively. From 2019 to 2023, estimated standardized numbers of US adults diagnosed with IH were 30 563, 27 975, 27 859, 26 624, and 28 754 based on annual prevalence, and 82 027, 93 768, 101 766, 107 763, and 124 905 based on all-time prevalence. Conclusions: Annual prevalence estimates (i.e. proportions of individuals with diagnosed IH during each year of interest) remained consistent across the follow-up period, ranging from 10.5 to 12.1 per 100 000 persons, signifying the rarity of the diagnosis.